We are live on ! Find out more
DCMIC

Decheng Capital Management III (Cayman) Portfolio holdings

AUM $300M
1-Year Est. Return 15.74%
This Fund
S&P 500
This Quarter Est. Return
+9.76%
1 Year Est. Return
+15.74%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$267M
AUM Growth
-$8.62M
Cap. Flow
-$4.02M
Cap. Flow %
-1.5%
Top 10 Hldgs %
80.22%
Holding
28
New
2
Increased
1
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
ALP.PRN
Alabama Power Co 5.20% CL-A PRF
ALP.PRN
+$49.3M
2
AURA icon
Aura Biosciences
AURA
+$1.06M

Top Sells

Rank Stock Value
1
ALPN
Alpine Immune Sciences Inc
ALPN
+$48.3M
2
ILMN icon
Illumina
ILMN
+$10.5M
3
BYSI icon
BeyondSpring
BYSI
+$4.91M

Sector Composition

Rank Sector Weight
1 Healthcare 77.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALP.PRN
1
DELISTED
Alabama Power Co 5.20% CL-A PRF
ALP.PRN
$49.3M 18.45%
+6,708,288
New +$49.3M
ZNTL icon
2
Zentalis Pharmaceuticals
ZNTL
$302M
$36.7M 13.75%
1,824,583
– –
RXDX
3
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$27.5M 10.29%
250,000
– –
HLTH
4
DELISTED
Cue Health Inc. Common Stock
HLTH
$18.6M 6.96%
8,980,909
– –
RCUS icon
5
Arcus Biosciences
RCUS
$3.64B
$18M 6.73%
869,790
– –
ILMN icon
6
Illumina
ILMN
$28.4B
$16.3M 6.12%
83,123
-50,659
-38% -$10.5M
ALBO
7
DELISTED
Albireo Pharma Inc
ALBO
$13.5M 5.04%
623,342
– –
TXG icon
8
10x Genomics
TXG
$6.61B
$13.1M 4.9%
359,554
– –
PACB icon
9
Pacific Biosciences
PACB
$368M
$12M 4.48%
1,463,872
– –
HZNP
10
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$8.98M 3.36%
78,900
– –
TERN
11
DELISTED
Terns Pharmaceuticals
TERN
$7.27M 2.72%
714,285
– –
WHWK
12
Whitehawk Therapeutics
WHWK
$271M
$6.75M 2.53%
526,329
– –
MRSN
13
DELISTED
Mersana Therapeutics
MRSN
$5.3M 1.98%
36,171
– –
ACET icon
14
Adicet Bio
ACET
$74.7M
$5.19M 1.94%
36,250
– –
EQ icon
15
Equillium
EQ
$133M
$4.89M 1.83%
4,447,308
– –
AURA icon
16
Aura Biosciences
AURA
$826M
$3.08M 1.15%
293,333
+83,333
+40% +$1.06M
SGEN
17
DELISTED
Seagen Inc. Common Stock
SGEN
$2.96M 1.11%
23,014
– –
ARGX icon
18
argenx
ARGX
$54.1B
$2.09M 0.78%
5,529
– –
APGN
19
DELISTED
Apexigen, Inc. Common Stock
APGN
$1.29M 0.48%
1,894,551
– –
WGS icon
20
GeneDx Holdings
WGS
$2.3B
$903K 0.34%
103,604
– –
SCYX icon
21
SCYNEXIS
SCYX
$52M
$867K 0.32%
69,444
– –
NAUT icon
22
Nautilus Biotechnolgy
NAUT
$115M
$540K 0.2%
300,000
– –
OWLT icon
23
Owlet
OWLT
$160M
$502K 0.19%
64,171
– –
NBSE
24
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$190K 0.07%
50,000
– –
BYSI icon
25
BeyondSpring
BYSI
$35.8M
– –
-4,958,143
Closed -$4.91M
1
2

Similar funds

IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
KBC
Key Bridge Compliance $319M AUM

Decheng Capital Management III (Cayman)'s Q4 2022 Portfolio in Review

As of Q4 2022, Decheng Capital Management III (Cayman) held 28 positions worth $267M, down 3.1% from $276M the previous quarter. Its ten largest holdings account for 80% of the portfolio.

Decheng Capital Management III (Cayman)'s Q4 2022 filing shows 2 new, 1 increased, 1 reduced and 2 closed positions. Its largest new stake was Alabama Power Co 5.20% CL-A PRF: 6,708,288 shares worth $49.3M. The largest sale was Alpine Immune Sciences Inc, an estimated $48.3M.

By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 99% a quarter earlier.

  • Decheng Capital Management III (Cayman)'s largest Q4 2022 buy was Alabama Power Co 5.20% CL-A PRF: 6,708,288 shares worth $49.3M.
  • Decheng Capital Management III (Cayman) added most to Aura Biosciences in Q4 2022, an estimated $1.06M increase.
  • Decheng Capital Management III (Cayman)'s biggest Q4 2022 reduction was Illumina, cutting an estimated $10.5M.
  • Decheng Capital Management III (Cayman) fully exited Alpine Immune Sciences Inc in Q4 2022, selling an estimated $48.3M.
  • Decheng Capital Management III (Cayman)'s ten largest holdings make up 80% of its $267M portfolio in Q4 2022.
  • Decheng Capital Management III (Cayman) opened 2 new positions and closed 2 in Q4 2022.
  • Decheng Capital Management III (Cayman)'s portfolio value fell 3.1% quarter-over-quarter to $267M.

Based on Decheng Capital Management III (Cayman)'s 13F filing for Q4 2022, filed 9 Feb 2023.